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Abstract
Background: The relationship between inflammation and blood pressure (BP) has been studied mainly in the
general population. In this study, we examined the association between inflammation and BP across a broader
range of inflammation observed in rheumatoid arthritis (RA) and non-RA outpatients.
Methods: We studied subjects from a tertiary care outpatient population with C-reactive protein (CRP) and BP
measured on the same date in 2009–2010; RA outpatients were identified using a validated algorithm. General
population data were obtained from the National Health and Nutrition Examination Survey (NHANES) as comparison.
To study the cross-sectional association between CRP and BP in the three groups, we constructed a generalized
additive model. Longitudinal association between CRP and BP was examined using a repeated-measures linear
mixed-effects model in RA outpatients with significant change in inflammation at two consecutive time points.
Results: We studied 24,325 subjects from the outpatient population, of whom 1811 had RA, and 5561 were from
NHANES. In RA outpatients, we observed a positive relationship between CRP and systolic BP (SBP) at CRP < 6 mg/L and
an inverse association at CRP ≥ 6 mg/L. A similar inverse U-shaped relationship was observed in non-RA outpatients. In
NHANES, we observed a positive relationship between CRP and SBP as demonstrated by previous studies. Longitudinal
analysis in RA showed that every 10 mg/L increase in CRP was associated with a 0.38 mmHg reduction in SBP.
Conclusions: Across a broad range of CRP observed in RA and non-RA outpatients, we found an inverse U-shaped
relationship between CRP and SBP, highlighting a relationship not previously observed when studying the
general population.
Keywords: Inflammation, Blood pressure, Rheumatoid arthritis
Background
Inflammation is associated with elevated blood pressure
(BP) in the general population [1, 2]. In rheumatoid
arthritis (RA), the levels of inflammation, as measured
by C-reactive protein (CRP) can be 10-fold higher than in
the general population. Whether the relationship between
inflammation and BP remains the same under these
conditions has not been closely studied [3, 4]. Studying
the association between inflammation and BP is particu-
larly important in RA; cardiovascular (CV) risk is 1.5–2.0
times higher compared to individuals from the general
population of similar age, sex, and CV risk factors [5–7].
This excess risk is attributed to inflammation [8].
There is also increasing evidence that inflammation
may modify traditional risk factors such that higher
levels of inflammation are associated with lower choles-
terol levels [9–11]. However, these lower cholesterol
levels are not associated with reduced CV risk; in RA,
any given level of cholesterol may confer a higher CV
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risk than expected based on general population-based
studies due to the added effect of inflammation [10, 12].
Few studies have examined closely the relationship be-
tween inflammation and BP levels, and whether a similar
modification may be occurring. Since both inflammation
and BP are associated with an increased risk of cardio-
vascular disease (CVD) [13–16], understanding the rela-
tionship between the two can provide insight into
pathways linking inflammation and CV risk not only in
RA, but also in the general population.
The objective of this study was to examine the associ-
ation between inflammation and BP in RA compared to
a non-RA outpatient cohort, and a general population
cohort. We hypothesize that the relationship between in-
flammation and BP may differ at the higher levels of in-
flammation observed in RA and other inflammatory
conditions compared to levels observed in the general
population.
Methods
Study populations
General population cohort
The National Health and Nutrition Examination Survey
(NHANES) served as the general population control for
this study [17]. The most recent NHANES data on CRP
and BP spans from 1 January 2009 to 31 December
2010. Thus, this time frame was used to select data for
all subjects in this study. Additionally, we studied only
subjects aged 18 years or older.
Outpatient population
To obtain a broader range of CRP values, we examined
the data on all outpatients followed at two large tertiary
hospitals, Brigham and Women’s Hospital (BWH) and
Massachusetts General Hospital (MGH), Boston, MA,
USA, with clinical data on approximately 7.2 million
patients. BWH and MGH share one electronic medical
record (EMR) system. The Partners Research Data
Repository (RPDR) [18] enabled efficient extraction of
de-identified clinical data across the two institutions.
Using the same inclusion criteria applied to NHANES,
the outpatient population consisted of adult patients
aged 18 years and older, who had CRP and BP mea-
sured on the same day at an outpatient visit between 1
January 2009 and 31 December 2010. For the primary
analysis we used the first same-day CRP and BP mea-
surements of each subject. Inpatients were not included
to reduce potential confounding from severe conditions
such as sepsis.
RA outpatient population and non-RA outpatient
population
We defined a subset of the outpatient population with a
validated diagnosis of RA, identified using a validated
and published algorithm with a positive predictive value
of 94% [19, 20], as the RA outpatient population. For
this cohort, we additionally extracted longitudinal data
on subjects who had a change in CRP ≥ 10 mg/L be-
tween two time points and also had BP measurements at
the two time points. We defined the rest of the out-
patient population, subjects not diagnosed with RA, as
the non-RA outpatient population.
CRP and BP measurements
In the NHANES cohort, CRP was measured using a
high-sensitivity assay with latex-enhanced nephelometry
[21]. Three consecutive BP measurements were obtained
by certified examiners using a sphygmomanometer after
participants had rested quietly while sitting for 5 min
[22]. For the analysis, we only included subjects with
valid BP readings for all three attempts. In the outpatient
population, CRP was measured using the high-sensitivity
CRP assay, performed in the clinical laboratories at Part-
ners Healthcare using standardized methods [23]. BP is
a required measurement at all outpatient visits at Part-
ners Healthcare, obtained by trained healthcare pro-
viders, and entered as structured data into the EMR. BP
values are recorded as systolic blood pressure (SBP) and
diastolic blood pressure (DBP).
Statistical analysis
For the primary analysis, we focused on the association
between CRP and SBP because it is the main target of
BP intervention studies of CVD risk [13]. The CRP
levels were common-log-transformed to normalize the
distribution. Using graphical techniques, we visualized the
relationship between CRP (common-log-transformed) and
SBP in the RA outpatient population. From this graph, we
observed that the relationship was non-linear. Thus, we
constructed a generalized additive model with penalized
splines as the approach to study the association be-
tween CRP and SBP, adjusting for age (continuous),
gender, and race (non-Hispanic white/non-Hispanic
black/other races); electronic prescription data were
used to obtain information on anti-hypertensive medi-
cation, statins, methotrexate (MTX), and tumor necro-
sis factor inhibitors (TNFi), as a binary value for ever/
never use. Since we are interested in studying a non-
linear association between the variables, we applied the
generalized additive model. This approach uses semi-
parametric methods to enable modeling of non-linear
association [24]. Additionally, we tested the associa-
tions between CRP and DBP, pulse pressure (PP), and
mean arterial pressure (MAP) using the same model.
The same methods were also applied to the non-RA
outpatient population and NHANES.
In the RA outpatient population, we performed a lon-
gitudinal study examining the association between the
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changes in inflammation and changes in BP. In RA, hav-
ing a high level of inflammation is typically a temporary
state due to an RA flare or inadequate response to treat-
ment. Thus, subjects with RA routinely have large
changes in CRP in the course of routine care, providing
an opportunity to study the association between longitu-
dinal changes in inflammation and BP. For this study,
we focused on patients with RA who had an increase or
decrease in CRP by ≥ 10 mg/L, which is considered a
significant change in inflammation [25, 26]. We applied
linear mixed effect models to account for correlation be-
tween repeated measures within subjects to examine the
associations between changes in CRP and changes in
SBP. We defined baseline as the day of their first same-
day CRP and BP measurements during the study period.
Model 1 was adjusted for baseline CRP and baseline
SBP. Model 2 was additionally adjusted for age at base-
line (continuous), gender, race (non-Hispanic white/non-
Hispanic black/other races), anti-hypertensive medica-
tion use at baseline (yes/no), and statin use at baseline
(yes/no). Model 3 was further adjusted for common RA
treatments at baseline - TNFi, MTX, and leflunomide,
which has a known association with elevated BP [27].
The potential effect of corticosteroids was also assessed
by further adjusting the model for corticosteroid use.
The same methods were applied to examine the associa-
tions between change in CRP and change in DBP, PP,
and MAP.
Sensitivity analysis was performed by trimming ex-
treme measurements of CRP (< 0.5% and > 99.5%) in
both cohorts to prevent the strong influence of a small
number of extreme values. Covariate data including age,
gender, race, baseline anti-hypertensive medication use,
and baseline statin use were extracted in both outpatient
populations and NHANES.
To determine potential causes of elevated CRP in the
outpatient population, we randomly selected 50 subjects
with CRP in the highest decile. We reviewed medical re-
cords on or near the date of the elevated CRP and anno-
tated the cause of the elevated CRP as attributed by the
treating physician.
For all statistical analyses, a two-sided P value <0.05
was considered to be statistically significant. All data
analyses were performed using SAS 9.4 (SAS Institute
Inc., Cary, NC, USA) and R version 3.2.2 (R Development
Core Team) statistical packages. This study protocol was
approved by the Partners Healthcare Institutional Review
Board.
Results
A total of 24,325 subjects were included in the outpatient
population, of whom 1811 had RA (RA outpatient popula-
tion) and 22,514 did not (non-RA outpatient population).
We studied 5561 subjects from the NHANES cohort
(Table 1). Subjects with RA were generally older with mean
age 60.4 years, compared to 54.0 years in the non-RA out-
patient population and 47.9 years in NHANES. The median
CRP was 3.4 mg/L (range 0.20–126.90 mg/L) in the RA
outpatient population, 2.2 mg/L (range 0.10–416.20 mg/L)
in the non-RA outpatient population, and 0.18 mg/L
Table 1 Clinical characteristic of subjects in the RA outpatient population, non-RA outpatient population and the general population
(NHANES)
Characteristic Outpatient population
N = 24,325
NHANES*
N = 5561
RA
N = 1811
Non-RA
N = 22,514
Age, years, mean (SD) 60.39 (13.97) 54.00 (15.55) 47.88 (18.49)
Female (%) 80.18 61.03 50.46
Ethnicity (%)
Non-Hispanic white 80.51 80.40 48.48
Non-Hispanic black 5.63 5.46 16.90
Others 13.86 14.14 34.62
Anti-hypertensive medication use (%) 23.47 25.38 30.30
Statin medication use (%) 10.38 12.92 17.59
CRP, mg/L, median (IQR) 3.40 (1.40, 9.00) 2.20 (0.90, 5.80) 0.18 (0.07, 0.43)
SBP, mmHg, mean (SD) 129.92 (17.12) 126.48 (16.81) 122.14 (18.26)
DBP, mmHg, mean (SD) 75.62 (11.47) 76.07 (15.66) 69.30 (11.92)
PP, mmHg, mean (SD) 54.30 (14.57) 50.41 (17.94) 52.83 (17.51)
MAP, mmHg, mean (SD) 93.72 (11.76) 92.87 (13.65) 86.91 (11.74)
RA rheumatoid arthritis, NHANES National Health and Nutrition Examination Survey, CRP C-reactive protein, SBP systolic blood pressure, DBP diastolic blood pressure,
PP pulse pressure, MAP mean arterial pressure
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(range 0.01 to 18.01 mg/L) in NHANES. Additional
characteristics for the RA population include 51.49% anti-
cyclic citrullinated peptide (anti-CCP) positive, 41.25% on
MTX, and 22.25% on TNFi.
Associations between CRP and BP in the RA and non-RA
outpatient populations and NHANES
The ranges of CRP were 0.20−126.90 mg/L in the RA
outpatient population, 0.10–416.20 mg/L in the non-RA
outpatient population, and 0.01 –18.01 mg/L in NHANES.
In both the RA and non-RA outpatient populations, we
observed an inverse U-shaped association between CRP
and SBP (Figs. 1 and 2).
In the RA outpatient population, a positive association
was observed between CRP and SBP in subjects with
CRP < 5.94 mg/L. We observed an inverse relationship
between CRP and SBP at CRP ≥ 5.94 mg/L (Fig. 1). A
similar relationship was observed between CRP and SBP
in the non-RA outpatient population. A positive rela-
tionship was observed between CRP and SBP until CRP
levels reached 8.39 mg/L. There was an inverse relationship
between CRP and SBP at CRP ≥ 8.39 mg/L. In comparison,
within NHANES, we observed a positive association be-
tween CRP and SBP.
The relationships between CRP and PP also differed
in the RA and non-RA outpatient populations com-
pared to NHANES, whereby there was an inverse rela-
tionship between CRP and PP after a threshold level of
CRP was reached (Additional file 1: Figure S1B and
Additional file 2: Figure S2B). The relationships be-
tween CRP and DBP and MAP were qualitatively more
similar across the RA, non-RA and the general popula-
tion cohorts (Additional file 1: Figure S1A and S1C,
Additional file 2: Figure S2A and S2C). Findings from the
sensitivity analysis with trimming of extreme measurements
of CRP were similar to the main analysis (Additional file 3:
Figure S3 and Additional file 4: Figure S4).
RA and other inflammatory arthritides (e.g. psoriatic
arthritis, gout) comprised the largest percentage of
subjects with CRP in the highest decile (34%), followed
by infection (22%). Connective tissue diseases, including
systemic lupus erythematosus, Sjogren’s syndrome, and
myositis, were attributed by the treating rheumatologist
to the elevated CRP in 10% of cases. Inflammatory bowel
disease was attributed as the cause of the elevated CRP
in 8% of cases and the etiology of the elevated CRP
could not be determined in 14% of subjects.
Longitudinal association between CRP and BP in RA
We identified 355 patients with RA from the RA out-
patient population who had CRP changes defined as
≥ 10 mg/L or ≤ − 10 mg/L at ≥ 2 consecutive time
points between 1 January 2009 and 1 June 2012. The
median baseline CRP in this population was 9.7 (25th
percentile 3.4, 75th percentile 25.4) mg/L. The mean SBP
was 131.2 mmHg (SD 18.4) and DBP was 75.9 mmHg
Fig. 1 The relationship between C-reactive protein levels (CRP) and
systolic blood pressure with 95% confidence intervals, in the
rheumatoid arthritis (RA) outpatient population and the general
population (National Health and Nutrition Examination Survey
(NHANES)). RA outpatient population CRP range 0.20–126.90 mg/L;
NHANES CRP range 0.01–18.01 mg/L
Fig. 2 The relationship between C-reactive protein (CRP) levels and
systolic blood pressure with 95% confidence intervals, in the
non-rheumatoid arthritis (RA) outpatient population and the general
population (National Health and Nutrition Examination Survey (NHANES)).
Non-RA outpatient population CRP range 0.10–416.20 mg/L;
NHANES 0.01–18.01 mg/L
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(SD 11.9). Of the 355 subjects with RA, 80.3% were female
and 78.9% were white. The mean temporal interval be-
tween two time points in which CRP and BP were con-
comitantly recorded was 0.41 year (SD: 0.40). At baseline,
27.6% subjects were on anti-hypertensive medications, 10.
7% on statin, 38.3% on MTX, 27.3% on a TNFi, and 15.2%
on leflunomide.
Among patients with RA with significant inflammation
change, as defined by CRP ≥ 10 mg/L, we observed a sig-
nificant inverse association between the change in CRP
and change in BP. Every 10 mg/L increase in CRP was as-
sociated with a 0.38-mmHg reduction in SBP. This rela-
tionship remained the same after adjusting for age,
gender, race, anti-hypertensive medication, and statin use.
As well, this relationship remained the same after add-
itionally adjusting for potent immunomodulators such
as TNFi, MTX, and leflunomide (Table 2). The associ-
ation between CRP and SBP also remained the same
after adjusting for corticosteroid use (β -0.38, 95% CI
− 0.66, − 0.10, p = 0.007). An increase in CRP was also
associated with reductions in DBP, PP, and MAP
(Additional file 5: Table S1).
Discussion
In summary, our study corroborates previous reports of
a positive linear association between CRP and SBP.
However, we found that this relationship was true only
in the range of CRP typically observed in the general
population. At higher CRP levels, we observed an in-
verse association between CRP and SBP. This inverse re-
lationship was present not only in RA, but also in the
non-RA outpatient population. Thus, previous studies
on the association between inflammation and SBP may
have shed light on only half the relationship. Studying a
broader range of CRP levels in subjects allowed us to fill
in information on the relationship between inflammation
and BP between the two extremes, “normal” and those
with sepsis. Studying data in a large population allowed
us to identify this relationship.
Based on the cross-sectional study, a subject with
CRP≥ 10mg/L would lie at the right side of the inverse
U-shaped curve in Fig. 1. Based on the cross-sectional
data, a reduction in inflammation would be associated
with an increase in SBP. Indeed, this relationship was
confirmed in the longitudinal analysis, where a reduction
in CRP was associated with a modest increase in SBP.
The association remained significant after adjusting for
potential confounders including age, gender, and com-
mon RA treatments.
These findings may explain the absence of association
between CRP and the outcome of hypertension in RA in
a previous study [28]. The previous study used a binary
outcome for hypertension, which would not detect a non-
linear relationship between CRP and BP. Our findings are
also consistent with current knowledge on the relationship
between sepsis, an extreme form of inflammation, and BP.
Uncontrolled inflammation in sepsis is linked with endo-
thelial dysfunction and hypotension [29, 30]. Treatment
and resolution of sepsis is associated with normalization
of BP. Based on our data, we observed a similar though
less severe pattern in subjects with RA, and in non-RA
subjects with evidence of inflammation defined as elevated
CRP. While there are studies on BP in sepsis, to our
knowledge, there were no studies examining subjects in
this intermediate group with mild to moderate CRP
elevation.
The significance of our findings relates more to popula-
tion health rather CV risk management at the individual
level. In a recent study using data from the Atherosclerosis
Risk in Communities study, investigators found that a
1-mmHg reduction in SBP was associated with substan-
tial reduction in cardiovascular events at the population
level [31]. Thus, the modest changes in SBP observed
with changes in CRP may influence CV risk among
subjects with inflammatory diseases. Taken in a larger
context, the results of this study suggest a similar
phenomenon to the lipid paradox in RA [32]. In the
lipid paradox, lower lipids have not been associated
with lower CV risk. Patients with RA with a reduction
in inflammation, which is considered protective against
CV risk, also experience an increase in low-density
lipoprotein cholesterol (LDL-C) [10, 33], a marker of
increased CV risk. In this study, reduction in inflamma-
tion (suggesting lower CV risk) was associated with
modest increases in BP (suggesting higher CV risk).
Thus, inflammation may be modifying the relationship
between traditional CV risk factors, adding blood pres-
sure to the list of factors already known to be altered in
RA, including lipids and insulin resistance [34, 35].
Additionally, we observed that compared to the gen-
eral population, the RA population on average had
higher BP, at any given CRP level. While the mean BP at
most CRP levels would not reach the threshold for
Table 2 Association between change in C-reactive protein
(CRP) (per 10 mg/L) and change in systolic blood pressure (SBP)
(per mmHg) in patients with rheumatoid arthritis with significant
changes in inflammation
Models* Change in SBP per 10 mg/L increase in CRP
Coefficient (95% CI) P value
Model 1 − 0.38 (− 0.66, − 0.11) 0.007
Model 2 − 0.38 (− 0.66, − 0.11) 0.007
Model 3 − 0.38 (− 0.66, − 0.10) 0.007
*Model 1, adjusted for baseline CRP level and SBP; model 2, additionally
adjusted for age (continuous), gender (male/female), race (non-Hispanic white/
non-Hispanic black/other races), anti-hypertensive medication use (yes/no),
and statin medication use (yes/no); model 3, additionally adjusted for tumor
necrosis factor inhibitors medication use (yes/no), leflunomide use (yes/no),
and methotrexate medication use (yes/no)
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classification as hypertension [36], these modest differ-
ences in SBP may also explain the known elevated risk
for CVD in RA compared to the general population. The
higher SBP in the outpatient population is likely due to
a higher prevalence of hypertension in a clinic-based co-
hort compared to the general population.
The influences of inflammation on traditional CV risk
factors may partially explain the underestimation of CV
risk observed in several studies [37–39]. From the man-
agement perspective, this study adds to the current data
on the importance of assessing CV risk among subjects
with RA and those with other inflammatory diseases,
when their disease is well-controlled. Assessing CV risk
during active inflammatory disease may lead to measure-
ments of both lipids and blood pressures that are lower
than if the patients were in low disease activity or
remission.
Limitations of this study include studying only patients
who had CRP measured as part of routine care. As CRP
is measured when a clinician is concerned about inflam-
mation, the analysis likely includes the majority of pa-
tients with any type of inflammatory condition, which
was a goal of the study. While CRP is only one of many
markers of inflammation, it has been widely adopted for
use across multiple conditions and was selected because
it is a clinically interpretable test. Additionally, we ad-
justed for additional factors that may confound the asso-
ciation between CRP and BP, but not all factors were
available for inclusion in the models. We examined
known major confounders including age, gender, race,
and anti-hypertensive and RA treatments.
We note that there are two potential confounders
where ascertainment can be suboptimal using EMR data:
non-steroidal anti-inflammatory drugs (NSAIDs) and
corticosteroids. NSAIDs were not included in our models
because the majority of NSAID use is over the counter not
requiring a prescription, and so analysis of prescriptions
for NSAIDs may be biased [40, 41]. The anticipated effect
of NSAID use is elevated CRP, regardless of CRP levels,
which would attenuate the association between elevated
CRP and lower SBP. Thus, we anticipate that NSAID use
would generally bias our findings towards the null. We ob-
served no difference in association between change in CRP
and change in SBP after adjusting for corticosteroids.
Another potential concern was differences in treat-
ment among subjects with RA who had increases or de-
creases in their CRP, explaining the inverse association
between CRP and SBP at higher CRP levels. When
examining baseline treatments, we observed a similar
percentage of biologic disease-modifying anti-rheumatic
drug use among subjects who experienced a decrease in
CRP (12.4%) compared to that among subjects who ex-
perienced an increase in CRP (12.5%). Other potential
confounders not measured were the duration and doses
of therapy. Last, the study population was selected from
a tertiary care center and may not be generalizable to
other community-based centers.
While identifying mechanisms for our findings is be-
yond the scope of this study, one potential mediator of
this association is endothelial function, which plays an
important role in vasomotor function and regulation of
BP [42]. Patients with RA have increased arterial stiff-
ness, which is attributed to endothelial dysfunction [43].
Treatment with the potent RA anti-inflammatory agent,
TNFi, is associated with a significant reduction in dis-
ease activity and significant improvements in endothelial
dependent and independent vasodilation of the brachial
artery in patients with RA [44]. There is also evidence to
suggest that endothelial dysfunction is influenced by
other inflammatory cytokines in addition to TNF [45].
Together the data suggest that inflammation may im-
pact endothelial function, vasomotor function, and
regulation of BP. In line with these findings, we ob-
served an inverse U-shaped association between CRP
and PP, where PP is considered closely associated with
endothelial function [46].
Conclusions
In conclusion, our study suggests that CRP, used as a
marker of inflammation, has a biphasic relationship
with SBP when examining the relationship across the
range of CRP levels observed in RA and in the out-
patient setting. At lower levels of inflammation typically
observed in the general population, an increase in CRP
is associated with an increase in SBP. In RA and other
states where a patient has elevated levels of inflamma-
tion, the relationship changes, such that CRP is associ-
ated with a decrease in SBP. When inflammation is
mitigated, the relationship normalizes such that BP
may increase as inflammation decreases, until general
population levels of CRP are reached. While the
changes in SBP were modest, they highlight a new rela-
tionship between CRP and BP not characterized previ-
ously. From the population health perspective, modest
changes in SBP can have a substantial impact on CV
risk. The pathways mediating these changes remains to
be seen, however there is evidence to suggest endothe-
lial function may play an important role. These data
suggest a need to reevaluate our current approach to
interpreting BP and CV risk in the setting of active in-
flammation in RA and other conditions, and the need
for a better understanding of the pathways linking in-
flammation and BP regulation. Future studies in co-
horts with detailed data on both inflammation and CV
risk factors and outcomes are needed to determine the
clinical significance of changes in inflammation on
blood pressure and overall CV risk.
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